č. 8/2014 - Onkologie

ACTA MEDICINAE 8/2014 Onkologie
Kompletní literatura
2
Predikce incidence a prevalence nádorových onemocnění a počtu léčených onkologických
pacientů v ČR v letech 2015 a 2020
2
Predikce počtu pacientů indikovaných k vyšetření PET/CT v ČR: první výsledky projektu PET/CT-CZ(Q)
3
Doporučení pro léčbu sarkomů měkkých tkání Evropské společnosti klinické onkologie, ESMO
3
Novinky v hormonální léčbě karcinomu prsu před a po ASCO 2014
3
Antracykliny v první linii léčby karcinomu prsu mohou být účinnější, než si myslíme – kazuistika
4
Nemalobuněčný karcinom plic – novinky v léčbě
4
Nemalobuněčný karcinom plic s přestavbou genu EML4-ALK – nové možnosti léčby
5
Možnosti systémové léčby gastroenteropankreatických neuroendokrinních tumorů
5
Gastrointestinální stromální tumor – základní algoritmus diagnostiky a léčby
6
Výběr optimální sekvence v léčbě metastatického renálního karcinomu
6
Karcinom ovaria – současnost a novinky v léčbě
6
Stanovení strategie léčby u metastatického melanomu
7
Role parenterální výživy v podpůrné onkologické léčbě – nový pohled
7
Novinky v léčbě průlomové bolesti
7
Qutenza v léčbě chemoterapií indukované polyneuropatie
7
HPV infekce u mužů
doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Ústav
zdravotnických informací a statistiky ČR, Praha RNDr. Tomáš Pavlík, Ph.D. | RNDr. Ondřej Májek, Ph.D. | Mgr. Jakub Gregor, Ph.D.
IBA, LF MU, Brno RNDr. Jan Mužík, Ph.D. IBA, LF MU, Brno, ÚZIS ČR, Praha RNDr. Denisa Malúšková | Mgr. Jana Koptíková, Ph.D. |
Mgr. Zbyněk Bortlíček IBA, LF MU, Brno prof. MUDr. Jitka Abrahámová, DrSc. Thomayerova nemocnice, Praha
doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Ústav
zdravotnických informací a statistiky ČR, Praha prof. MUDr. Jiří Petera, Ph.D. | doc. MUDr. Jiří Doležal, Ph.D. Fakultní nemocnice
Hradec Králové prof. MUDr. Vlastimil Válek, CSc. Fakultní nemocnice Brno RNDr. Tomáš Pavlík, Ph.D. | RNDr. Ondřej Májek, Ph.D.
Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno Mgr. Michal Burger Institut biostatistiky a analýz,
Lékařská fakulta Masarykovy univerzity, Brno, Ústav zdravotnických informací a statistiky ČR, Praha Mgr. Jakub Gregor, Ph.D. |
Mgr. Jana Koptíková, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno
RNDr. Jan Mužík, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Ústav zdravotnických
informací a statistiky ČR, Praha
MUDr. Kateřina Kubáčková Onkologická klinika 2. LF UK a FN Motol, Praha
prof. MUDr. Luboš Petruželka, CSc. | MUDr. Zuzana Ušiaková | MUDr. Michal Vočka | MUDr. Lucie Hussarová Onkologická
klinika 1. LF UK a VFN v Praze a Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha, Ústav radiační onkologie
Nemocnice Na Bulovce v Praze
doc. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a VFN v Praze
prof. MUDr. Jana Skřičková, CSc. | MUDr. Ondřej Venclíček | MUDr. Bohdan Kadlec, Ph.D. |
MUDr. Marcela Tomíšková | MUDr. Lenka Jakubíková, Ph.D. | Jana Špaldová
Klinika nemocí plicních a tuberkulózy LF MU a FN Brno
prof. MUDr. Miloš Pešek, CSc. Klinika tuberkulózy a respiračních nemocí FN Plzeň
prof. Dr. med. Michael Hilker, FETCS Universitätsklinikum Regensburg, Německo
RNDr. Petr Grossmann FN Plzeň, Šiklův patologicko-anatomický ústav Plzeň
MUDr. Jiří Tomášek, Ph.D. Klinika komplexní onkologické péče MOÚ Brno, LF MU, Brno
MUDr. Zdeněk Linke Onkologická klinika FN Motol a 2. LF UK, Praha
MUDr. Hana Študentová Onkologická klinika FN Olomouc
MUDr. Josef Chovanec, Ph.D. Oddělení gynekologické onkologie, MOÚ Brno
MUDr. Eugen Kubala Klinika onkologie a radioterapie LF UK a FN Hradec Králové
MUDr. Petr Beneš Interní oddělení, Nemocnice Na Homolce, Praha
MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti ARK LF MU a FN u sv. Anny v Brně
MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti ARK LF MU a FN u sv. Anny v Brně
doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN Praha
Predikce incidence a prevalence nádorových onemocnění
a počtu léčených onkologických pacientů v ČR
v letech 2015 a 2020
doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy
univerzity, Brno, Ústav zdravotnických informací a statistiky ČR, Praha RNDr. Tomáš Pavlík, Ph.D. |
RNDr. Ondřej Májek, Ph.D. | Mgr. Jakub Gregor, Ph.D. IBA, LF MU, Brno RNDr. Jan Mužík, Ph.D. IBA,
LF MU, Brno, ÚZIS ČR, Praha RNDr. Denisa Malúšková | Mgr. Jana Koptíková, Ph.D. | Mgr. Zbyněk
Bortlíček IBA, LF MU, Brno prof. MUDr. Jitka Abrahámová, DrSc. Thomayerova nemocnice, Praha
1 Curado, M. P. – Edwards, B. – Shin, H. R., et al. (eds.): Cancer incidence in five continents, roč. IX. IARC Scientific Publications č. 160.
International Agency for Research on Cancer, Lyon, 2007, vyhledáno
8. 5. 2014, dostupné z: http://ci5.iarc.fr.
2 Ferlay, J. – Soerjomataram, I. – Ervik, M., et al.: GLOBOCAN 2012 v1.0,
cancer incidence and mortality eorldwide: IARC CancerBase č. 11 [internet]. International agency for research on cancer, Lyon, 2013. Vyhledáno 5. 6. 2014, dostupné z: http://globocan.iarc.fr.
3 Dušek, L. – Mužík, J. – Kubásek, M., et al.: Epidemiology of malignant
tumors in the Czech Republic [internet]. Masaryk University, Brno,
2005, vyhledáno 8. 5. 2014, dostupné z: http://www.svod.cz.
4 Clerc, L. – Jooste, V. – Lejeune, C., et al.: Cost of care of colorectal
cancers according to health care patterns and stage at diagnosis in
France. Eur J Health Econ, 2008, 9, s. 361–367.
5 Pavlík, T. – Májek, O. – Mužík, J., et al.: Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015:
the analysis of the Czech National Cancer Registry. BMC Public Health,
2012, 12, s. 117.
6 Maddams, J. – Utley, M. – Miller, H.: Projections of cancer prevalence in the United Kingdom, 2010–2040. Br J Cancer, 2012, 107,
s. 1195–1202.
7 Mariotto, A. B. – Yabroff, K. R. – Sbal, Y., et al.: Projections of the cost
of cancer care in the United States: 2010–2020. J Natl Cancer Inst, 2011,
103, s. 117–128.
8 Travis, L. B.: The epidemiology of second primary cancers. Cancer
Epidemiol Biomarkers Prev, 2006, 15, s. 2020–2026.
Predikce počtu pacientů indikovaných k vyšetření
PET/CT v ČR: první výsledky projektu PET/CT-CZ(Q)
doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz, Lékařská fakulta Masarykovy
univerzity, Brno, Ústav zdravotnických informací a statistiky ČR, Praha prof. MUDr. Jiří Petera,
Ph.D. | doc. MUDr. Jiří Doležal, Ph.D. Fakultní nemocnice Hradec Králové prof. MUDr. Vlastimil
Válek, CSc. Fakultní nemocnice Brno RNDr. Tomáš Pavlík, Ph.D. | RNDr. Ondřej Májek, Ph.D.
Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno Mgr. Michal Burger
Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno, Ústav zdravotnických
informací a statistiky ČR, Praha Mgr. Jakub Gregor, Ph.D. | Mgr. Jana Koptíková, Ph.D. Institut
biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno RNDr. Jan Mužík, Ph.D. Institut
biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno,
Ústav zdravotnických informací a statistiky ČR, Praha
1 Dušek, L. – Mužík, J. – Kubásek, M. – Koptíková, J. – Žaloudík, J. –
Vyzula R.: SVOD.cz – Epidemiologie zhoubných nádorů v České republice (internetová stránka). Masarykova univerzita, 2007, vyhledáno
3. 7. 2014, dostupné na www.svod.cz.
2 Ferlay, J. – Autier, P. – Boniol, M. – Heanue, M. – Colombet, M. –
Boyle, P.: Estimates of the cancer incidence and mortality in Europe
in 2006. Ann Oncol, 2007, 18, s. 581–592.
3 Ferlay, J. – Steliarova-Foucher, E. – Lortet-Tieulent, J. – Rosso, S. –
Coebergh, J. W. – Comber, H., et al.: Cancer incidence and mortality
patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer,
2013, 49, s. 1374–1403.
4 Dyba, T. – Hakulinen, T.: Comparison of different approaches to incidence prediction based on simple interpolation techniques. Stat
Med, 2000, 19, s. 1741–1752.
5 Verdecchia, A. – De Angelis, G. – Capocaccia, R.: Estimation and
projections of cancer prevalence from cancer registry data. Stat Med,
2002, 21, s. 3511–3526.
6 De Angelis, R. – Sant, M. – Coleman, M. P. – Francisci, S. – Baili,
P. – Pierannunzio, D., et al.: Cancer survival in Europe 1999–2007 by
country and age: results of EUROCARE-5-a population-based study.
Lancet Oncol, 2014, 15, s. 23–34.
7 Warren, J. L. – Klabunde, C. N. – Schrag, D. – Bach, P. B. – Riley, G. F.:
Overview of the SEER-Medicare data: content, research applications,
and generalizability to the United States elderly population. Med Care,
2002, 40 (dopl.), s. IV-3-18.
8 Czernin, J. – Allen-Auerbach, M. – Schelbert, H. R.: Improvements
in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med, 2007, 48, dopl. 1, s. 78S-88S.
9 Czernin, J. – Allen-Auerbach, M. – Nathanson, D. – Herrmann, K.:
PET/CT in Oncology: Current Status and Perspectives. Curr Radiol Rep,
2013, 1, s. 177–190.
10 Farwell, M. D. – Pryma, D. A. – Mankoff, D. A.: PET/CT imaging in cancer: Current applications and future directions. Cancer, 19. 6. 2014.
11 Umbehr, M. H. – Muntener, M. – Hany, T. – Sulser, T. – Bachmann, L.
M.: The role of 11C-choline and 18F-fluorocholine positron emission
tomography (PET) and PET/CT in prostate cancer: a systematic review
and meta-analysis. Eur Urol, 2013, 64, s. 106–117.
12 Ferda, J. – Kastner, J. – Ferdová, E. – Mírka, H. – Hora, M. – Hes, O.,
et al.: Zobrazení karcinomu prostaty na molekulární úrovni – naše
zkušenosti. Ces Radiol, 2012, 66, s. 289–295.
13 Dusek, L., et al.: Czech cancer care in numbers 2008–2009. Praha,
Grada Publishing, 2009.
14 Blaha, M. – Janča, D. – Klika, P. – Mužík, J. – Dušek, L.: Project I-COP –
architecture of software tool for decision support in oncology. In:
Blobel, B. – Hasman, A. – Zvárová, J. (eds.): Data and knowledge for
medical decision support: Proceedings of the EFMI special topic conference, 17-19 April 2013, Prague, Czech Republic: IOS Press; 2013.
15 Pavlík, T. – Májek, O. – Mužík, J., et al.: Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015:
the analysis of the Czech National Cancer Registry. BMC Public Health,
2012, 12, s. 117.
ACTA MEDICINAE 8/2014 ONKOLOGIE Kompletní literatura
Doporučení pro léčbu sarkomů měkkých tkání Evropské
společnosti klinické onkologie, ESMO
MUDr. Kateřina Kubáčková Onkologická klinika 2. LF UK a FN Motol, Praha
1 ESMO/European Sarcomas Network Working Group. Soft tissue
and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012, 23 (7),
s. vii92–vii99.
Novinky v hormonální léčbě karcinomu prsu
před a po ASCO 2014
prof. MUDr. Luboš Petruželka, CSc. | MUDr. Zuzana Ušiaková | MUDr. Michal Vočka | MUDr. Lucie
Hussarová Onkologická klinika 1. LF UK a VFN v Praze a Ústřední vojenská nemocnice –
Vojenská fakultní nemocnice Praha, Ústav radiační onkologie Nemocnice Na Bulovce v Praze
1 ASCO Annual Meeting Abstracts, 30. května – 3. června 2014.
2 Bachelot, T., et al.: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive,
human epidermal growth factor receptor 2-negative metastatic
­breast cancer with prior exposure to aromatase inhibitors: a GINECO
study. J Clin Oncol, 2012, 30, s. 2718–2724.
3 Baselga, J., et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 2012.
4 Di Leo, A. – Jerusalem, G. – Petruzelka, L., et al.: Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant
500 mg in postmenopausal women with estrogen receptor-positive
advanced breast cancer. J Clin Oncol, 2010.
5 Jones, S. E., et al.: Randomized phase III study of docetaxel compared
with paclitaxel in metastatic breast cancer. J Clin Oncol, 2005.
6 Kaufman, B., et al.: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human
epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase
III TAnDEM study. J Clin Oncol, 2009.
7 Ellis, M. J., et al.: Whole-genome analysis informs breast cancer res­
ponse to aromatase inhibition. Nature, 2012.
8 Finek, J. – Petruželka, L., et al.: První česko-moravský konsensus hormonální léčby karcinomu prsu. 2014 (v přípravě k tisku).
9 Finn, R. S., et al.: PD 0332991, a selective cyclin D kinase 4/6 inhibitor,
preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res, 2009.
10 Finn, R. S., et al.: Final results of a randomized Phase II study of PD
0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs. letrozole alone for first-line treatment of ER+/
HER2- advanced breast cancer (PALOMA-1; TRIO-18). AACR, abstrakt
CT101, 2014.
11 Giordano, S. H., et al.: Systemic therapy for patients with advanced
human epidermal growth factor receptor 2-positive breast cancer:
American Society of Clinical Oncology Clinical Practice Guideline.
J Clin Oncol, 2014.
12 Hober, J., et al.: Higher efficacy of letrozole in combination with tras­
tuzumab compared to letrozole monotherapy as first-line treatment
in patients with HER2-positive, hormone-receptor-positive metastatic
breast cancer—results of the eLEcTRA trial. Breast, 2012.
13 Jerusalem, G., et al.: Safety analysis of BOLERO-3: a phase 3 trial of daily everolimus (EVE) vs. placebo (PBO), both with weekly trastuzumab
(TRAS) and vinorelbine in trastuzumab-resistant, advanced ­breast
cancer. San Antonio Breast Cancer Symposium; abstrakt S2-02, 2013.
14 Lee, A. V. – Davidson, N. E.: Genomics, drug approval, and optimal
treatment duration. Nat Rev Clin Oncol, 2014.
15 Martin, M., et al.: S1-7. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced
breast cancer—First efficacy results from the LEA study. Cancer Res,
2012.
16 Montemurro, M., et al.: Humen epidermal growth factor receptor 2
(HER2) positive and hormone receptor-positive breast cancer: new
insights into molecular interactions and clinical implications. Ann Oncol, 2013.
17 Palmieri, C., et al.: Breast cancer: Current and future endocrine therapies. Molecular and Cellular Endocrinology, 2014.
18 Petruželka, L. – Vočka, M. – Matějů, M.: Metastazující hormonálně
dependentní karcinomy prsu – doporučené postupy nebo jen obecné
léčebné principy ve světle nových poznatků? 2014.
19 Piccart, M., et al.: Everolimus for postmenopausal women with
advanced breast cancer: updated results of the BOLERO-2 phase III
trial [abstrakt 559]. J Clin Oncol, 2012.
20 Piccart, M., et al.: Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results
from BOLERO-2. Přednáška, abstrakt LBA1. European Breast Cancer
Conference (EBCC-9), 2014.
21 Swain, S. M., et al.: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival
results from a randomised, double-blind, placebo-controlled, phase
3 study. Lancet Oncol, 2013.
22 Seidman, A. D., et al.: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with
trastuzumab for all HER-2 overexpressors and random assignment
to trastuzumab or not in HER-2 nonoverexpressors: Final results of
Cancer and Leukemia Group B protocol 9840. J Clin Oncol, 2008.
23 Schwartzberg, L. S., et al.: Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
Oncologist, 2010.
24 Yardley, D. A., et al.: Results of ENCORE 301, a randomized, phase II,
double-blind, placebo-controlled study of exemestane with or with­
out entinostat in postmenopausal women with locally recurrent or
metastatic estrogen receptor-positive (ER+) breast cancer progres­
sing on a nonsteroidal aromatase inhibitor (AI). J Clin Oncol, 2013.
25 Yardley, D. A., et al.: Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic
breast cancer: a phase II Trial of the Sarah Cannon Oncology Research
Consortium. Clin Breast Cancer, 2011.
26 Moore, H. C. F.: abstrakt LBA505, prezentováno na ASCO Annual
­Meeting, 30. 5. – 3. 6. 2014, Chicago.
27 Pagani, O. – Regan, M. M. – Walley, B. – Fleming, G. F. – Colleoni, M. –
Lang, I. – Gomez, H. L. – Tondini, C. – Burstein, H. J., et al.: Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E)
plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in
premenopausal women with hormone receptor-positive (HR+) early
breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. J Clin
Oncol, 2014, 32, abstrakt LBA1.
28 Piccart, M.: abstrakt LBA9200, prezentováno na ASCO Annual Meeting, 30. 5. – 3. 6. 2014, Chicago.
29 Hortobagyi, G. N.: abstrakt LBA9500, prezentováno na ASCO Annual
Meeting, 30. 5. – 3. 6. 2014, Chicago.
Antracykliny v první linii léčby karcinomu prsu mohou být
účinnější, než si myslíme – kazuistika
doc. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a VFN v Praze
1 Gennari, A. – D’Amico, M.: Anthracyclines in the management of
metastatic breastcancer: state of the art. EJC supplements 9, 2011, 2,
s. 11–15.
2 Rivera, E.: Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist, 2003, 8, dopl. 2, s. 3–9.
3 Gennari, A. – Piccininno, M. – Sarti, S.: The role of liposomal anthracyclines in metastatic breast cancer. Current Breast Cancer Reports,
2013, 5, s. 23–30.
4 Doval, D. C. – Dutta, K. – Batra, U. – Talwar, V.: Neoadjuvant chemotherapy in breast cancer: review of literature. J Indian Med Assoc, 2013,
111, s. 629–631.
5 Lyseng-Williamson, K. A. – Duggan, S. T. – Kratiny, G. M.: Pegylated
liposomal doxorubicin: a guide to its use in various malignancies.
BioDrugs, 2013, 27, s. 533–540.
ACTA MEDICINAE 8/2014 ONKOLOGIE Kompletní literatura
Nemalobuněčný karcinom plic – novinky v léčbě
prof. MUDr. Jana Skřičková, CSc. | MUDr. Ondřej Venclíček | MUDr. Bohdan Kadlec, Ph.D. |
MUDr. Marcela Tomíšková | MUDr. Lenka Jakubíková, Ph.D. | Jana Špaldová
Klinika nemocí plicních a tuberkulózy LF MU a FN Brno
1 Dušek, L. – Májek, O. – Mužík, J. – Kostíková, J. – Pavlík, T. – Skřičková, J.: Epidemiologie zhoubných nádorů plic, průdušnice a průdušek
v ČR. In: Skřičková, J. – Kolek, V., et al.: Základy moderní pneumoonkologie. Maxdorf, Praha, 2012.
2 Giroux, D. J. – Rami-Porta, R. – Chansky, K., et al.: The IASLC Lung
Cancer Staging Project: data elements for the prospective project.
J Thorac Oncol, 2009, 4, s. 679–83.
3 Pešek, M.: Nemalobuněčný karcinom plic. EUNI, dostupné z: http://
www.euni.cz/tema.php?, vyhledáno 22. 9. 2014.
4 Škarda, J. – Überall, I. – Tichý, T. – Matěj, R.: Novinky v klasifikaci
adenokarcinomů plic a potenciální prognostické a prediktivní faktory u nemalobuněčných plicních karcinomů. Cesk Patol, 2011, 47,
s. 168–172.
5 Travis, W. D. – Brambilla, E. – Noguchi, M., et al.: International associa­
tion for the study of lung cancer / american thoracic society / european respiratory society international multidisciplinary classification
of lung adenocarcinoma. J Thorac Oncol, 2011, 6, s. 244–285.
6 Skřičková, J. – Kolek, V., et al.: Základy moderní pneumoonkologie.
Maxdorf, Praha, 2012.
7 Paz-Ares, L. – de Marinis, F., et al.: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for
advanced non-squamous non-small-cell lung cancer (PARAMOUNT):
a double-blind, phase 3, randomised controlled trial. Lancet Oncol,
2012, 13, s. 247–255.
8 Lunch, T. J. – Bell, D. W. – Sordella, R., et al.: Activating mutations
in the epidermal growth factor receptor underlying responsiveness
of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350,
s. 2129–2139.
9 Bonomi, P.: Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer, 2003, 41, s. S43–S48.
10 Duffield, E. L. – Watkins, C. L. – Armour, A. A. – Fukuoka, M.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New
England Journal of Medicine, 2009, 361, s. 947–957.
11 Kim, E. S. – Hirsch, V. – Mok, T., et al.: Gefitinib versus docetaxel in
previously treated non-small-cell lung cancer: a randomised Phase
III trial (INTEREST). Lancet, 2008, 372, s. 1809–1818.
12 Pešek, M.: Nemalobuněčný karcin plic. EUNI, dostupné z: http://www.
euni.cz/tema.php?, vyhledáno 22. 9. 2014.
13 Thatcher, N. – Chány, A. – Parikh, P., et al.: Gefitinib plus best sup­
portive care in previously treated patients with refractory advanced
non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
Lancet, 2005, 366, s. 1527–1537.
14 Shepherd, F. A. – Pereira, J. R. – Ciuleanu, T., et al.: Erlotinib in previously
treated non-small-cell lung cancer. N Engl J Med, 2005, 353, s. 123–132.
15 Pešek, M. – Skřičková, J. – Kolek, V., et al.: Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v ČR. Stud Pneumol Phtiseol,
2009, 69, s. 62–68.
16 Yang, J. Ch. – Schuler, M. – Yamamoto, N. – O’Byrne, K. – Hirsh, V. –
Mok, T., et al.: LUX-Lung 3: a randomized, open-label, Phase III study
of afatinib vs cisplatin/pemetrexed as 1st-line treatment for patients
with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol, 2012, 30, dopl., abstrakt LBA7500.
17 Wu, Y.-L.: LUX-Lung 6: A randomized, open-label, Phase III study of
afatinib (A) vs. gemcitabine/cisplatin (GC) as first-line treatment for
Asian patients (pts.) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. American Society of Clinical Oncology, Chicago, 2. 6. 2013. J Clin Oncol, 2013, 31, dopl.; abstrakt 8016.
18 Yang, L. V. – Sequist, M. – Schuler, T. – Mok, N. – Yamamoto, K. –
O’Byrne, V. – Hirsh, S. – Geater, C. – Zhou, D. – Massey, V. – Zazulina, Y.-L.: Overall survival in patients with advanced NSCLC harboring
common (Del19/L858R) EGFR mutations: analysis of two large, open-label phase III studies of afatinib vs chemotherapy, LUX-Lung 3 and
LUX-Lung 6. ASCO 2014.
19 Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature,
2007, 448, s. 561–566. Wong, D. W. – Leung, E. L. – So, K. K., et al.:
The EML4-ALK fusion gene is involved in various histologic types of
lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer, 2009, 115, s. 1723–1733.
20 Shaw, A. T. – Salomon, B.: Targeting anaplastic lymphoma kinase in
lung cancer. Clin Cancer Res, 2011, 17, s. 2081–2085.
21 Rikova, K. – Guo, A. – Zeng, Q., et al.: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 2007,
131, s. 1190–1203.
22 Takeuchi, K. – Choi, Y. L. – Togashi, Y., et al.: KIF5B-ALK, a novel fu­
sion oncokinase identified by an immunohistochemistrybased diagnostic system for ALK-positive lung cancer. Clin Cancer Res, 2009, 15,
s. 3143–3149.
23 Shaw, A. T. – Trap, B. Y. – Salomon, B. J., et al.: Effect of crizotinib on
overall survival in patients with advanced non-small-cell lung cancer
harbouring ALK gene rearrangement: a retrospective analysis. Lancet
Oncol, 2011, 12, s. 1004–1012.
24 Reck, M. – von Pawel, J. – Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line
therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol, 2009, 27, s. 2415.
25 Reck, M.: Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients
progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. 2013, ASCO Annual Meeting, J Clin
Oncol, 2013, 31, dopl.; abstrakt LBA8011.
26 Hanna, N.: LUME-Lung 2: A multicentre, randomized, double-blind,
Phase III study of nintedanib plus pemetrexed vs. placebo plus pemetrexed in patients with advanced non-squamous non-small cell
lung cancer (NSCLC) after failure of first-line chemotherapy. American
Society of Clinical Oncology, Chicago, 2. 6. 2013. J Clin Oncol, 2013,
31, dopl.; abstrakt 8034.
27 Thatcher, N. – Hirsch, F. R. – Szczesna, A., et al.: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC)
chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus
GC alone in the first-line treatment of patients (pts) with stage IV
squamous non-small cell lung cancer (sq-NSCLC). J Clin Oncol, 2014,
32, 5s (dopl.; abstrakt 8008).
28 Perol, M. – Ciuleanu, T. E. – Arrieta, O. – Prabhash, K. – Syrigos, K. N.,
et al.: REVEL: A randomized, double-blind, phase III study of docetaxel
(DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo
(PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. J Clin Oncol, 2014, 32, 5s (dopl.; abstrakt LBA8006).
Nemalobuněčný karcinom plic s přestavbou
genu EML4-ALK – nové možnosti léčby
prof. MUDr. Miloš Pešek, CSc. Klinika tuberkulózy a respiračních nemocí FN Plzeň
prof. Dr. med. Michael Hilker, FETCS Universitätsklinikum Regensburg, Německo
RNDr. Petr Grossmann FN Plzeň, Šiklův patologicko-anatomický ústav Plzeň
1 Bowle, D. W. – Weickhardt, A. J. – Doebele, R.C. – Camidge, D. R. –
Jimeno, A.: Crizotinib for the treatment of patients with advanced
non-small cell lung cancer. Drugs of Today, 2012, 48, s. 271–282.
2 Camidge, D. R. – Doebwele, R. C.: Treating ALK-positve lung cancer – early successes and future challenges. Nat Rev Clin Oncol, 2012,
9, s. 268–277.
3 Pešek, M, – Grossmann, P. – Mukenšnabl, P. – Minárik, M.: První zkušenosti s vyšetřováním zlomu genu ALK (anaplastické lymfomové
kinázy) a s podáním crizotinibu u vybraných nemocných s nemalobuněčnými karcinomy plic (NSCLC). Studia Pneumologica Phthiseol,
2012, 72, s. 159–162.
4 Ryška, A. – Petruželka, L. – Skřičková, J. – Kolek, V. – Hajduch, M. –
Matěj, R. – Uvirová, M. – Pešek, M. – Dvořáčková, J. – Hornychová,
H.: Interdisciplinární konsenzus pro prediktivní vyšetřování u nemalobuněčného karcinomu plic (NSCLC) – aktualizace 2012. Studia Pneumologica Phthiseol, 2012, 72, 3, s. 168.
5 Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in nonn-small cell lung cancer. Nature,
2007, 448, s. 561–566.
6 Yang, J. – Zhang, X. – Su, J. – Chen, H. – Tian, H. – Juany, Y. – Xu, C. –
Wu, Y. L.: Concomitant EGFR mutation and EML4-ALK gene fusion
in non-small cell lung cancer. Journal of Clin Oncol, 2011, ASCO An­
nual Meeting Proceedings (post-Meeting Edition), 29, dopl., abstrakt
10517.
ACTA MEDICINAE 8/2014 ONKOLOGIE Kompletní literatura
Možnosti systémové léčby gastroenteropankreatických
neuroendokrinních tumorů
MUDr. Jiří Tomášek, Ph.D. Klinika komplexní onkologické péče MOÚ Brno, LF MU, Brno
1 Yao, J. C. – Hassan, M. – Phan, A., et al.: One hundred years after „carcinoid“: epidemiology of and prognostic factors for neuroendocrine
tumors in 35,825 cases in the United States. J Clin Oncol, 2008, 26,
s. 3063–3072.
2 Rinke, A. – Miller, H. H. – Schade-Brittinger, C., et al.: Placebo-controlled, double-blind, prospective, randomized study on the effect of
octreotide LAR in the control of tumor growth in patiens with metastatic neuroendocrine midgut tumors: a report from the PROMID
Study Group. J Clin Oncol, 2009, 27, s. 4656–4663.
3 Caplin, M. – Ruszniewski, P. – Pavel, M., et al.: A randomized, double-blind, placebo-controlled study of Lanreotide Antiproliferative
Response in patients with gastroenteropancreatic NeuroEndocrine
Tumors (CLARINET). European Cancer Congress, 2013, abstrakt 3, prezentováno 28. 9. 2013.
4 Klener, P. – Klener, P. jr.: Nová protinádorová léčiva a léčebné strategie
v onkologii. Praha, Grada Publishing, 2010.
5 Öberg, K. – Ferone, D. – Kaltsas, G., et al.: ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy.
Neuroendocrinology, 2009, 90, s. 209–213.
6 Raymond, E. – Dahan, L. – Raoul, J. L., et al.: Sunitinib malate for the
treatment of pancreatic neuroendocrine tumors. N Engl J Med, 2011,
364, s. 501–513.
7 Faivre, S. – Nicolli, P. – Raoul, J. L., et al.: Updated overall survival
analysis from a phase III study of sunitinib vs placebo in patients with
advanced, unresectable pancreatic neuroendocrine tumor. ESMO
Meeting, 2012, abstrakt 11550.
8 Yao, J. C. – Shah, M. H. – Ito, T., et al.: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 2011, 364, s. 514–523.
9 Pavel, M., et al.: Consensus guidelines for the management of pa­
tients with liver and other distant metastases from neuroendocrine
neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology, 2012, 95, s. 157–176.
Gastrointestinální stromální tumor – základní algoritmus
diagnostiky a léčby
MUDr. Zdeněk Linke Onkologická klinika FN Motol a 2. LF UK, Praha
1 Blanke, C. – Demetri, G., et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEJM, 2002, 347,
s. 472–480.
2 Verweij, J. – Casali, P. G. – Zalcberg, J. – Le Cesne, A. – Reichardt, P. –
Blay, J. Y.: Progression free survival in gastrointestinal stromal tumor
with high a low dose imatinib: randomised trial. Lancet, 2004, 364,
s. 1127–1134.
3 Rankin, C. – Von Mehren, M. – Blanke, C. – Benjamin, R. – Fletcher,
C. D. M. – Bramwell, V.: Dose effect of imatinib in patients with metastatic GIST: Phase III Sarcoma Group Study S0033 (abstrakt 9005),
Proc ASCO, 2004, 23, s. 815.
4 Van Glabbeke, M. – Verweij, J., et al.: Initial and late resistance to
imatinib in advanced gastro-intestinal stromal tumor are predicted
by different prognostic factors, an eortc-isg-agitg study. J Clin Oncol,
2005, 23, s. 5795–5804.
5 Blay, J. Y. – Le Cesne, A., et al.: Prospective multicenter randomized
phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of
treat­ment beyond 1 year: The French Sarmoma Group. J Clin Oncol,
25, s. 1107–1113.
6 Rios, M. – La Cesne, A., et al.: Interruption of imatinib in GIST patients
with advanced diasease after one year of treatment: Updated results
of the prospective French Sarcoma Group randomized phase III trial
on long term survival. ASCO Ann Meet, 2007, abstrakt 10016.
7 Van Glabbeke, M. M. – Lazar, K. – Rankin, C., et al.: Comparison of
two doses of imatinib for the treatment of unresectable or metastatic
gastrointestinal stromal tumors (GIST): A meta-metaanalysis based on
1.640 patients. ASCO Ann Meet, 2007, abstrakt 10004.
8 Heindrich, M. C. – Maki, R. G. – Corless, C. L., et al.: Sunitinib response in imatinib-resistant GIST correlates with KIT and PDGFR mutation
status. J Clin Oncol, 2006, 24, s. 9502.
9 Demetri, G. D. – van Oosterom, A. T., et al.: Efficacy and safety of
sunitinib in patients with advanced gastointestinal stromal tumour
after failure of imatinib: a randomised controlled trial. Lancet, 2006,
s. 6736–6746.
10 Van Oosterom, A. T. – Dumez, H. – Desai, J., et al.: Combination signal transduction inhibition: A phase I/II trial of the oral m-TOR-inhibitor everolimus (E, RAD001) and imatinib mesylate in patients with
gastrointestinal stromal tumors refractory to imatinib mesylate. J Clin
Oncol, 2004, 22, s. 3002.
11 Demetri, G. D.: Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine
kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase
I trial. ASCO Annual Meeting, 2007, Sarcina.
12 Von Mehren, M. – Reichardt, P. – Casali, P. G. – Blay, J.: A phase I study of AMN107 alone and in combination with imatinib in patients
(pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) –
Study Update. ASCO Meeting, 2007.
13 Data on file, Novartis UK Ltd. Study No STI571B2222. Open, randomized, phase II study of Glivec in patients with unresectable or
metastatic malignant gastrointestinal stromal tumors expressing
c-kit. Report 15. 12. 2003.
14 Chandrajit, P. R. – DeMatteo, R. P.: Prognostic factors for primary GIST:
prime time for personalized therapy? Annals of Surgical Oncology, 15,
1, s. 4–6.
15 De Matyek, R. P. – Antonescu, C. R., et al.: Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor
(GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. ASCO, 2008.
16 De Matyek, R. P. – Owzar, K., et al.: Adjuvant imatinib mesylate in­
creases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North
American Intergroup Phase III trial ACOSOG Z9001. ASCO, 2008.
17 Zhan, W. H.: Efficacy and safety of adjuvant post-surgical therapy with
imatinib in patients with high risk of relapsing GIST. JCO, 25, 18S.
18 Nilsson, B. – Sjolund, K. – Kindblom, L. C., et al.: Adjuvant imatinib
treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer, 2007, 96,
s. 1656–1658.
19 Scandinavian Sarcoma Group: Study comparing 12 months versus
36 months of imatinib in the treatment of gastrointestinal stromal
tumor (GIST). SSGXVIII/AIO. Dostupné z: http:www.clinicaltrials.gov/
ct/show/NCT00116935?order=1, vyhledáno 25. 10. 2007.
20 European Organisation for Research and Treatment of Cancer:
Imatinib mesylate or observation only in treating patients who
have undergone surgery for localized gastrointestinal stromal tumor- EORTC-62024. Dostupné z: www.clinicaltrials.gov/ct/show/
NCT00103168?order=1, vyhledáno 25. 10. 2007.
21 RTOG S-0132 protocol. A phase II trial of neoadjuvant / adjuvant STI-571
(Gleevec NSC 716051) for primary and recurrent operable malignant
GIST expressing the KIT receptor tyrosine kinase (CD117). Dostupné z: www.rtog.org/members/protocols/s0132/s0132.pdf, vyhledáno 3. 10. 2007.
22 Demetri, G. D. – Reichardt, P. – Kang, Y. K. – Blay, J. Y – Joensuu, H. –
Maki, R. G. – Rutkowski, P. – Hohenberger, P. – Gelderblom, H. – Leahy, M. G. – von Mehren, M. – Schöffski, P. – Blackstein, M. E. – Le
Cesne, A. – Badalamenti, G. – Xu, J. M. – Nishida, T. – Laurent, D. –
Kuss, I. – Casali, P. G., on behalf of GRID Investigators: Randomized
phase III trial of regorafenib in patients (pts) with metastatic and/or
unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): The
GRID Trial.
23 Rutkowski, P. – Bylina, E. – Klimczak, T. – Switaj, T. – Limon, J., et al.:
The outcome and predictive factors of sunitinib in advanced gastrointestinal stromal tumor (GIST) after imatinib failure—one institution
study. BMC Cancer, 2012, 12, s. 107.
24 ENESTg1: A randomized, open-label, multi-center phase III study to
evaluate the efficacy and safety of nilotinib versus imatinib in adult
patients with unresectable or metastatic gastrointestinal stromal tumor (GIST). http://clinicaltrials.gov/show/NCT00785785.
25 An open-label, multi-center, single arm study to evaluate the efficacy
of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatment. http://clinicaltrials.
gov/ct2/show/NCT00756509.
26 Randomized phase III trial comparing nilotinib 800 mg imatinib 800
mg for the treatment of patients with advanced and/or metastatic
gastrointestinal stromal tumor refractory to imatinib 400 mg. http://
clinicaltrials.gov/ct2/show/NCT00751036.
27 A phase II, non-randomized, open-label multicenter study of 5 years
adjuvant imatinib mesylate (Gleevec®) in patients at significant
risk of recurrence following complete resection of primary gastrointestinal stromal tumor (GIST). http://clinicaltrials.gov/ct2/show/
NCT00867113.
28 A phase II, open-label study of PTK787/ZK222584 in the treatment of
metastatic gastrointestinal stromal tumors (GIST) resistant to imatinib
mesylate. http://clinicaltrials.gov/ct2/show/study/NCT00117299.
29 Phase 2 study of oral AB1010 in non pre-treated, inoperable patients
with locally advanced / metastatic gastro-intestinal stromal tumor
(GIST). http://clinicaltrials.gov/ct2/show/NCT00998751.
30 An open-label study of AMG 706 in subject with advanced gastrointestinal stromal tumors (GISTs) who developed progressive disease
or relapsed while on imatinib mesylate. http://clinicaltrials.gov/ct2/
show/NCT00089960.
31 An open-label, phase II study to evaluate the biological activity of
cediranib (AZD2171) as measured by (F 18) fluoro 2 deoxy d glucose – positron emission tomography (FDG-PET) response, in patients
with metastatic gastro-intestinal stromal tumors (GISTs) resistant or
intolerant to imatinib mesylate. http://clinicaltrials.gov/ct2/show/
study/NCT00385203.
32 An phase II study of sorafenib in patients with metastatic or advanced gastrointestinal stromal tumors (GISTs) who failed to imatinib
and sunitinib. http://clinicaltrials.gov/ct2/show/NCT01091207.
33 A study evaluating STA-9090 in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST). http://clinicaltrials.
gov/ct2/show/NCT010339519.
34 Dasatinib first-line treatment in gastrointestinal stromal tumors.
A multi center phase II trial. http://clinicaltrials.gov/ct2/show/
NCT00568750.
35 Phase II study of crenolanib (CP-868,596), a selective and potent inhibitor of PDGFR, for the treatment of patients with advanced gastrointestinal stromal tumors with the D842-related mutations and
deletions, including the D842V mutation, in the PDGFRA gene. http://
clinicaltrials.gov/ct2/show/NCT01243346.
36 A study evaluating the safety, tolerability and pharmacokinetics of
GDC-0973 in combination with GDC-0941 when administered daily
in patients with locally advanced or metastatic solid tumor. http://
clinicaltrials.gov/ct2/show/NCT0133184.
37 A study evaluating GDC-0980 administered once daily in patients
with refractory solid tumors or non-Hodgkin‘s lymphoma. http://clinicaltrials.gov/ct2/show/NCT000997765.
ACTA MEDICINAE 8/2014 ONKOLOGIE Kompletní literatura
Výběr optimální sekvence v léčbě metastatického
renálního karcinomu
MUDr. Hana Študentová Onkologická klinika FN Olomouc
1 Négrier, S. – Gratis, G. – Pérol, D., et al.: Temsirolimus and bevacizumab or sunitinib, or interferon alfa and bevacizumab for patients with
advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Lancet Oncol, 2011, 12, s. 673–80.
2 Bracarda, S. – Bellmunt, J. – Melichar, B., et al.: Overall survival in patinets with metastatic renal cel carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine
kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
3 Motzer, R. J. – Barrios, C. H. – Kim, T. M., et al.: 1. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus
in patients with metastatic renal cell carcinoma. J Clin Oncol, 2014,
32, s. 2765–2772.
4 Steiner, F. – Chastonay, R. – Liewen, H., et al.: A pooled analysis of
sequential therapies with sorafenib and sunitinib in metastatic renal
cell carcinoma. Oncology, 2012, 82, s. 333–340.
5 Büchler, T. – Klapka, R. – Melichar, B., et al.: Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from
the Czech registry. Ann Oncol, 2012, 23, s. 395–401.
6 Rini, B. I. – Escudier, B. – Tomczak, P., et al.: Comparative effectiveness
of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS):
a randomised phase 3 trial. Lancet, 2011, 378, s. 1931–1939.
7 Hutson, T. – Escudier, B. – Esteban, E., et al.: Randomized phase III
trial of temsirolimus versus sorafenib as second-line therapy after
sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2014, 32, s. 760–767.
8 Motzer, R. J. – Escudier, B. – Oudars, S., et al.: Phase 3 trial of everolimus for metastatis renal cell carcinoma: final results and analysis of
prognostic factors. Cancer, 2012, 116, s. 4256–4265.
9 Motzer, R. J. – Porta, C. – Vogelzang, N. J., et al.: Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic
renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet
Oncol, 2014, 15, s. 286–96.
10 Iacovelli, R. – Carteni, G. – Sternberg, C. N., et al.: Clinical outcomes
in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. Eur J Cancer,
2013, 49, s. 2134–2142.
11 Busch, J. – Seidel, C. – Erber, B., et al.: Retrospective comparison of
triple-sequence therapies in metastatic renal cell carcinoma. Eur Urol,
2013, 64, s. 62–70.
12 Calvani, N. – Morelli, F. – Chiuri, V., et al.: Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal
cell carcinoma: are the two options alike? Med Oncol, 2013, 30, s. 578.
13 Heng, D. Y. – Mackenzie, M. J. – Vaishampayan, U. N., et al.: Primary
anti-vascular endothelial growth factor (VEGF)-refractory metastatic
renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol, 2012, 23, s. 1549–1555.
Karcinom ovaria – současnost a novinky v léčbě
MUDr. Josef Chovanec, Ph.D. Oddělení gynekologické onkologie, MOÚ Brno
1 ÚZIS ČR, NOR ČR 2013: Novotvary 2010 ČR.
2 Vaughan, S. – Coward, J. I. – Bast Jr., R. C., et al.: Rethinking ovarian
cancer: recommendations for improving outcomes. Nat Rev Cancer,
2011, 11, s. 719–725.
3 Dundr, P.: Prekancerózy endometria, děložní tuby a ovaria: přehled
současné problematiky. Česko-slovenská patologie, 2012, 1, s. 30–34.
4 Ramirez, I. – Chon, H. S. – Apte, S. M.: The role of surgery in the management of epithelial ovarian cancer. Cancer Control, 2011, 18, 1,
s: 22–30.
5 du Bois, A. – Reuss, A. – Pujade-Lauraine, E., et al.: Role of surgical
outcome as prognostic factor in advance epithelial ovarian cancer:
a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer, 2009, 115, 6, s. 1234–1244.
6 Skírnisdóttir, I. – Sorbe, B.: Prognostic factors for surgical outcome
and survival in 447 women treated for advanced (FIGO-stages III-IV)
epithelial ovarian carcinoma. Int J Oncol, 2007, 30, s. 727–734.
7 Harter, P. – du Bois. A. – Hahmann, M., et al: Surgery in recurrent
ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie
(AGO) DESKTOP OVAR trial. Ann Surg Oncol, 2006, 13, s. 1702–1710.
8 Markman, M.: Pharmaceutical management of ovarian cancer: cur­
rent status. Drug, 2008, 68, s. 771–789.
9 Modesitt, S. C. – Jazaeri, A. A.: Recurrent epithelial ovarian cancer:
pharmacotherapy and novel therapeutics. Expt Opin Pharmacother,
2007, 8, s. 2293–2305.
10 Poveda, A. – Vergote, I. – Tjulandin, S., et al.: Trabectidin plus pegylated doxorubicin in relapsed ovarian cancer outcomes in the partially
platinum-sensitive subpopulation of OVA-301 Phase III randomized
trial. Ann Oncol, 2011, 22, s. 39–48.
11 Engelen, M. J. – Snel, B. J. – Schapveld, M., et al.: Long-term morbidity of adjutant whole abdominal radiotherapy ( WAPRT ) or
chemotherapy for early stage ovaria cancer. Eur J Cancer, 2009, 45,
7, s. 1193–1200.
12 Burger, R. A. – Brady, M. F. – Bookman, M. A., et al.: Incorporation
of bevacizumab in the primary treatment of ovarian cancer. N Engl
J Med, 2011, 365, s. 2473–2483.
13 Perren, T. J. – Swart, A. M. – Pfisterer, J. N., et al.: A phase 3 trial of
bevacizumab in ovarian cancer. N Engl J Med, 2011, 365, s. 2484–2496.
14 Seimetz, D.: Novel monoclonal antibodies for cancer treatment: The
trifunctional antibody catumaxomab (Removab®). J Cancer, 2011, 2,
s. 309–316.
15 Poveda, A. – Ray-Coquard, I. – Romero, I., et al.: Emerging treatmens
strategies in recurrent platinum-sensitive ovarian cancer. Cancer Treat­
ment Reviews, 2014, 40, s. 366–375.
Stanovení strategie léčby u metastatického melanomu
MUDr. Eugen Kubala Klinika onkologie a radioterapie LF UK a FN Hradec Králové
1 Chapman, P. B. – Hauschild, A. – Robert, C., et al.: Improved survival
with vemurafenibin melanoma with BRAF V600E mutation. N Engl
J Med, 2011, 364, s. 2507–2516.
2 Hauschild, A. – Grob, J. J. – Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3
randomised controlled trial. Lancet, 2012, 380, s. 358–365.
3 Flaherty, K. T. – Puzanov, I. – Kim, K. B., et al.: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med, 2010, 363, s. 809–819.
4 Patel, J. D. – Krilov, L. – Adams, S., et al.: Clinical cancer advances
2013: annual report on progress against cancer from the American
Society of Clinical Oncology. J Clin Oncol, 2014, 32, s. 129–160.
5 Hauschild, A. – Grob, J. J. – Demidov, L. V., et al.: An update on
BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J Clin Oncol, 2013, 31, dopl., abstrakt 9013.
6 Chapman, P. B. – Hauschild, A. – Robert, C., et al.: Updated overall
survival (OS) results for BRIM-3, a phase III randomizedd, open-label,
multicenter trial comparing BRAF inhibitor vemurafenib (vem) with
dacarbazin in previously untreated patients with BRAFV600E – mutated melanoma. J Clin Oncol, 2012, 30, dopl., abstrakt 8502.
7 Ascierto, P. A. – Schadendorf, D. – Berliny, C., et al.: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF
mutations: anon-randomised, open-label phase 2 study. Lancet Oncol, 2013, 14, s. 249–256.
8 Flaherty, K. T. – Infante, J. R. – Daud, A., et al.: Combined BRAF and
MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med,
2012, 367, s. 1694–1703.
9 Eggermont, A., et al.: Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from
the EORTC 18071 phase III trial. J Clin Oncol, 2014, 32, dopl. 5s, abstrakt
9008.
10 Schadendorf, D. – Hodi, F. S. – Robert, C., et al.: Pooled analysis of
long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur
J Cancer, 2013, 49, dopl., abstrakt 24LBA.
11 Da Silva, I. – Perelman, R. O., et al.: Association of natural killer (NK)
cell exhaustion with melanoma progression. J Clin Oncol, 2014, 32,
dopl. 5s, abstrakt LBA9099.
12 Ascierto, P. A. – Simone, E. – Giannarelli, D., et al.: Sequencing of
BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med, 2012, 10, s. 107.
13 Hodi, F. S., et al.: Long-term survival of ipilimumab-naive patients
(pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol, 2014,
32, dopl. 5s, abstrakt 9002.
14 Topalian, S. L. – Hodi, F. S. – Brahmer, J. R., et al.: Safety, activity,
and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med,
2012, 366, s. 2443–2454.
15 Hamid, O. – Robert, C. – Daud, A., et al.: Safety and tumor responses
with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med, 2013, 369,
s. 134–144.
16 Weber, J. S. – Kudchadkar, R. R. – Yu, B., et al.: Safety, effıcacy, and
biomarkers of nivolumab with vaccine in ipilimumab-refractory or
naive- melanoma. J Clin Oncol, 2013, 31, s. 4311–4318.
17 Atkins, M. B., et al.: Phase 2, multicenter, safety and efficacy study of
pidilizumab in patients with metastatic melanoma. J Clin Oncol, 2014,
32, dopl. 5s, abstrakt 9001.
18 Segal, N. H., et al.: Preliminary data from a multi-arm expansion study
of MEDI4736, ananti-PD-L1 antibody. P J Clin Oncol, 2014, 32, dopl. 5s,
abstrakt 3002.
19 Puzanov, I., et al.: Phase 1 study of the BRAF inhibitor dabrafenib (D)
with or without the MEK inhibitor trametinib (T) in combination with
ipilimumab (Ipi) for V600E/Kmutation–positive unresectable or metastatic melanoma (MM). J Clin Oncol, 2014, 32, dopl. 5s, abstrakt 2511.
20 Kudchadkar, R. R., et al.: A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma. J Clin Oncol, 2014, 32, dopl. 5s, abstrakt 9098.
21 Gajewski, T. F.: Molecular profıling of melanoma and the evolution
of patient-specifıc therapy. Semin Oncol, 2011, 38, s. 236–242.
22 Mesina, J. L. – Fenstermacher, D. A. – Eschrich, S., et al.: 12-chemokine gene signature identifıes lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep, 2012,
2, s. 765.
23 Kudchadkar, R. – Gibney, G. – Sondak, V. K.: Integrating molecular
biomarekers into current clinical management in melanoma. Methods
Mol Biol, 2014, 1102, s. 27–42.
24 Paraiso, K. H. – Smalley, K. S.: Making sense of MEK1 mutations in
intrinsicand acquired BRAF inhibitor resistance. Cancer Discov, 2012,
ACTA MEDICINAE 8/2014 ONKOLOGIE Kompletní literatura
2, s. 390–392.
25 Sullivan, R. J. – Flaherty, K. T.: Resistance to BRAF-targeted therapy
in melanoma. Eur J Cancer, 2013, 49, s. 1297–1304.
26 Liu, D. – Liu, X. – Xing, M.: Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to
BRAF/MEK inhibitors in melanoma cells. Cell Cycle, 2014, 13, s. 208–219.
27 Lezcano, C. – Lee, C. W. – Larson, A. R., et al.: Evaluation of stromal
HGF immunoreactivity as a biomarker for melanoma response to RAF
inhibitors. Mod Pathol, Epub 17. 1. 2014.
Role parenterální výživy v podpůrné onkologické
léčbě – nový pohled
MUDr. Petr Beneš Interní oddělení, Nemocnice Na Homolce, Praha
1 The Veterans Affairs Total Parenteral Nutrition Cooperative Study
Group: Perioperative total parenteral nutrition in surgical patients.
N Engl J Med, 1991, 325, s. 525–532.
2 Thorell, A. – Nygren, J. – Ljungqvist, O.: Insulin resistance: a marker
of surgical stress. Curr Op Clin Nutr Metab Care, 1999, 2, s. 69–78.
3 Gianotti, L. – Braga, M. – Nespoli, L., et al.: A randomized control­
led trial of preoperative oral supplementation with a specialized diet
in patients with gastrointestinal cancer. Gastroenterology, 2002, 122,
s. 1763–1770.
4 Prado, C. M. M. – Baracos, V. E. – McGargar, V. J., et al.: Body
com­position as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res, 2007, 13, s. 3264–3268.
5 Ries, A. – Trottenberg, P. – Elsner, F., et al.: A systematic review on the
role of fish oil for the treatment of cachexia in advanced cancer: An
EPCRC cachexia guidelines project. Palliative Med, 2012, 26, s. 294–304.
6 Shils, M. E. – Wright, W. L. – Turnbull, A. – Brescia, F.: Long-term parenteral nutrition through an external arteriovenous shunt – report
of a case. N Engl J Med, 1970, 283, s. 341–344.
7 Anděl, M. – Filip, K. – Brůček, P.: Dlouhá domácí parenterální výživa
cestou totálně implantovaného kanylovaného systému. Čas Lék čes,
1992, 131, s. 395–298.
8 Bozzetti, F. – Cozzaglio, L. – Biganzoli, E., et al.: Quality of life and
length of survival in advanced cancer patients on home parenteral
nutrition. Clin Nutr, 2002, 21, s. 281–288.
9 Gozzaglio, L. – Balzola, F. – Cosentino, F., et al.: Outcome on cancer
patients receiving home parenteral nutrition. J Parenter Enteral Nutr,
1997, 21, s. 339–342.
10 Scolapio, J. S. – Picco, M. F. – Tarrosa, V. B.: Enteral versus parenteral
nutrition: the patient‘s preference. J Parenter Enteral Nutr, 2002, 26,
s. 248–250.
Novinky v léčbě průlomové bolesti
MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti ARK LF MU a FN u sv. Anny v Brně
1 Hakl, M. – Hřib, R.: Farmakoterapie léčby onkologické bolesti. Interní
medicína pro praxi, 2007, 9, s. 229–300.
2 Kabelka, L. – Kozák, J. – Lejčko, J. – Sláma, O.: Doporučený postup
pro léčbu průlomové bolesti. Bolest, 2011, 14, dopl. 1.
3 Webster, L. R.: Breakthrough pain in the management of chronic persistent pain syndromes. Am J Manag Care, 2008, 14, s. 116–122.
4 Dickman, A.: Integrated strategies for the successful management
of breakthrough cancer pain. Curr Opin Support Palliat Care, 2011, 5,
s. 8–14.
5 Fortner, B. V. – Okon, T. A. – Portenoy, R. K.: A survey of pain-related
hospitalizations, emergency department visits, and physician office
visits reported by cancer patients with and without history of breakthrough pain. J Pain, 2002, 3, s. 38–44.
6 Bredenberg, S. – Duberg, M. – Lennernas, B., et al.: In vitro and in
vivo evaluation of new sublingual tablet system for rapidoromucosal
absorption using fentanyl citrate as the active substance. Eur J Pharm
Sci, 2003, 20, s. 327–334.
7 Darwish, M. – Kirby, M. – ]iang, J. G.: Effect of buccal dwell time
on the pharmacokinetic profile of fentanyl buccal tablet. Expert Opin
Pharmacother, 2007, 8, s. 2011–2016.
8 Darwish, M. – Tempero, K. – Kirby, M., et al.: Pharmacokinetics and
dose proportionality of fentanyl effervescent buccal tablets inhealthy
volunteers. Clin Pharmacokinet, 2005, 44, s. 1279–1286.
9 Davis, M.: Fentanyl pro breakthrough pain: a systematik review. Expert
Rev Neurither, 2011, 11, s. 1197–1216.
Qutenza v léčbě chemoterapií indukované polyneuropatie
MUDr. Marek Hakl, Ph.D. Centrum pro léčbu bolesti ARK LF MU a FN u sv. Anny v Brně
1 Ehler, E.: Neuropatická bolest u diabetické polyneuropatie. Neurologie
pro praxi, 2010, 11, s. 107–111.
2 Attal, N. – Cruccu, G. – Baron, R. – Haanpaa, M. – Hanson, P. –
Jensen, T. – Numikko, T.: EFNS guidelines on the pharmacological
treatment of neuropathic pain: 2009 revision. European Journal of
Neurology, 2009, 8, s. 1010–1018.
3 Backonja, M. – Wallace, M. – Blonsky, R. – Cutler, B., et al.: NGX-4010,
a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol, 2008,
7, s. 1106–1112.
4 Simpson, D. – Brown, S. – Tobias, J.: Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropaty. Neurology, 2008, 70, s. 2305–2313.
HPV infekce u mužů
doc. MUDr. Tomáš Fait, Ph.D. Gynekologicko-porodnická klinika 1. LF UK a VFN Praha
1 European Centre for Disease Prevention and Control: Introduction
of HPV vaccines in EU countries – an update. Stockholm, ECDC, 2012.
2 Fait, T. – Dvořák, V. – Skřivánek, A.. et al.: Epidemiologie genitálních
bradavic mezi ženami v ČR. Čes Gynek, 2012, 77, 4, s. 360–363.
3 Fenton, K. A. – Lowndes, C. M.: Recent trends in the epidemiology
of STI in the European Union. Sex Trans Infect, 2004, 80, s. 255–263.
4 Desai, S. – Wetten, S. – Woodhall, S. C., et al.: Genital warts and cost
of care in England. Sex Trans Infect, 2011, 87, 6, s. 464–468.
5 Garland, S. M. – Hernandez-Avila, M. – Wheeler, C. M., et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital
disease. NEJM, 2007, 356, s. 1928–1943.
6 Fairley, C. K. – Hocking, J. S. – Gurrin, L. C., et al.: Rapid decline in
presentation of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for
young women. Sex Transm Infect, 2009, 85, s. 499–502.
7 Gertig, D. M. – Brotherton, J. M. – Saville, M.: Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health, 2011, 8,
2, s. 171–178.
8 Gallagher, T. Q. – Derkay, C. S.: Recurrent respiratory papillomatosis.
Curr Opin Otolaryngol Head Neck Surg, 2008, 16, s. 645–655.
9 Dubová, J. – Vydrová, J. – Bendová, O., et al.: Výsledky vakcinace proti HPV u pacientů s rekurentní papilomatózou hrtanu. Prostrad Med,
2012, 13, s. 921–923.
10 D‘Sousa, G. – Kreimer, A. – Viscidi, R., et al.: Case-control study of
human papillomavirus and oropharyngeal cancer. NEJM, 2007, 356,
s. 1944–1956.
11 Gillison, M. L. – Broutian, T. – Pickard, R. K., et al.: Prevalence of oral
HPV infection in the United States, 2009–2010. JAMA, 2012, 15, 307,
s. 693–703.
12 Giuliano, A. R. – Palefsky, J. M. – Goldstone, S., et al.: Efficacy of
quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med, 2011, 364, 5, s. 401–411.
13 Palefsky, J. M. – Giuiliano, A. R. – Goldstone, S., et al.: HPV valine
against anal HPV infection and anal intraepithelial neoplasia. N Engl
J Med, 2011, 365, s. 1567–1585.
ACTA MEDICINAE 8/2014 ONKOLOGIE Kompletní literatura